GlassScriptPhysician profile
Anne Marie Gharib
NPI 1538129713
$22,954.11
in general payments reported to CMS, 2019-2025
25 companies · $8,650 in 2025
The $8,650 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,063 · 2022: $3,020 · 2023: $2,736 · 2024: $7,486 · 2025: $8,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Travel and Lodging: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,070.30 |
| Travel and Lodging | $2,801.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,483.55 | 2021-2025 | Avvigo Guidance System, Synergy, Watchman Flx |
| Recor Medical INC | $2,257.61 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Medtronic, INC. | $2,197.93 | 2023-2025 | Linq II, Reveal Linq, Corevalve Evolut R |
| Kestra Medical Technology Services, INC. | $2,046.76 | 2022-2025 | Assure Wcd |
| Penumbra, INC. | $2,017.53 | 2024-2025 | Indigo System, Penumbra System |
| Terumo Medical Corporation | $1,943.11 | 2022-2025 | Metacross Otw, Glidesheath Slender |
| Shockwave Medical, INC | $1,689.56 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,624.16 | 2021-2025 | Lifevest |
| Heartflow, INC. | $1,127.53 | 2022-2025 | Ffrct |
| Amgen INC. | $874.69 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $696.71 | 2022-2025 | Lokelma, Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $658.12 | 2022-2024 | Xarelto |
| Zoll Circulation INC | $503.38 | 2022-2024 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Biotronik INC. | $392.12 | 2022-2023 | Orsiro Mission |
| Abiomed | $384.20 | 2024-2025 | Impella |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361.42 | 2024-2025 | Ozempic, Wegovy |
| United Therapeutics Corporation | $354.46 | 2024 | |
| Bridgebio Pharma, INC. | $265.00 | 2025 | Attruby |
| Cvrx, INC. | $264.94 | 2024-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $156.36 | 2022-2025 | |
| Vital Connect, INC | $151.41 | 2023 | Vitalpatch Rtm |
| Alexion Pharmaceuticals, INC. | $146.39 | 2024 | Strensiq |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Celgene Corporation | $120.51 | 2022 | |
| Journey Medical Corporation | $111.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Gharib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.